Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graciaa

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
The Journal of Infectious Diseases|July 25, 2022
Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 InfectionHans P Verkerke, Gregory L Damhorst, Daniel S Graciaa, et al.
Vaccine|October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adultsVarun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
Research Square|February 23, 2022
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimersNarayanaiah Cheedarla, Hans P Verkerke, Sindhu Potlapalli, et al.
Medrxiv : the Preprint Server for Health Sciences|February 8, 2022
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimersNarayanaiah Cheedarla, Hans P Verkerke, Sindhu Potlapalli, et al.
Open Forum Infectious Diseases|March 10, 2023
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy TrialDean Follmann, Holly E Janes, Eric Chu, et al.
Science Translational Medicine|July 16, 2025
Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic targetSatheesh Chonat, Jayre A Jones, Seema R Patel, et al.
Iscience|November 15, 2023
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimersNarayanaiah Cheedarla, Hans P Verkerke, Sindhu Potlapalli, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Research Square|May 13, 2022
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim AnalysisEvan Anderson, Lisa Jackson, Nadine Rouphael, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Infectious Diseases|July 25, 2022
Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 InfectionHans P Verkerke, Gregory L Damhorst, Daniel S Graciaa, et al.
Vaccine|October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adultsVarun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
Research Square|February 23, 2022
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimersNarayanaiah Cheedarla, Hans P Verkerke, Sindhu Potlapalli, et al.
Medrxiv : the Preprint Server for Health Sciences|February 8, 2022
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimersNarayanaiah Cheedarla, Hans P Verkerke, Sindhu Potlapalli, et al.
Open Forum Infectious Diseases|March 10, 2023
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy TrialDean Follmann, Holly E Janes, Eric Chu, et al.
Science Translational Medicine|July 16, 2025
Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic targetSatheesh Chonat, Jayre A Jones, Seema R Patel, et al.
Iscience|November 15, 2023
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimersNarayanaiah Cheedarla, Hans P Verkerke, Sindhu Potlapalli, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Research Square|May 13, 2022
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim AnalysisEvan Anderson, Lisa Jackson, Nadine Rouphael, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 7